Cyclogyl®
Cyclopentolate 0.5%, 1%, 2% · ophthalmic solution
Mydriatics/Cycloplegics
Approved uses
Mydriasis and cycloplegia
Adults one or two drops of 0.5%, 1% or 2% solution, repeated in five to ten minutes if necessary; children the same, with a second application of 0.5% or 1% solution if necessary; small infants a single drop of 0.5% with pressure over the nasolacrimal sac for two to three minutes.
Contraindications
Hypersensitivity to any component of this preparation.
Ophthalmic solution, 0.5% (15 mL), 1% (2 mL, 5 mL, 15 mL), 2% (2 mL, 5 mL, 15 mL)
Anticholinergic that blocks the response of the iris sphincter and of the ciliary body accommodative muscle to cholinergic stimulation, producing pupillary dilation and paralysis of accommodation. Onset is rapid and duration shorter than atropine, with maximal cycloplegia 25 to 75 minutes after instillation.
Warnings & Precautions
- CNS disturbances: This preparation may cause CNS disturbances, especially in younger age groups, but they may occur at any age, especially with the stronger solutions.
- Concentration-dependent CNS risk: A mini review of the literature found systemic adverse drug reactions such as language problems, visual or tactile hallucinations and ataxia to be rare and mainly in patients with risk factors, and recommended avoiding the use of 2% cyclopentolate and instead employing solutions with lower concentrations, preferably with another mydriatic such as phenylephrine.
- Infant systemic absorption: Infants are especially prone to CNS and cardiopulmonary effects; use one drop of 0.5% per eye, apply pressure over the nasolacrimal sac for two to three minutes, and observe for at least 30 minutes.
- Systemic absorption: Compress the lacrimal sac by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption.
- IOP and angle closure: Mydriatics may transiently raise intraocular pressure, and untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure after instillation.
- Down syndrome: Caution when considering use.
- Feeding intolerance and necrotizing enterocolitis: Feeding intolerance may follow ophthalmic use in infants, and necrotizing enterocolitis may follow use in preterm infants; cases have been reported, but causality has not been established. It is recommended that feeding be withheld for 4 hours after examination.
- Hazardous activities while pupils are dilated: Patients should not drive or engage in other hazardous activities while pupils are dilated, and should protect eyes in bright illumination.
- Child's mouth: Warn parents not to get this preparation in their child's mouth and to wash their own hands and the child's hands after administration.
- Contamination: Do not touch dropper tip to any surface, as this may contaminate the solution.
- Drug interactions: May interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
- Not for injection: For topical ophthalmic use only.
Common Side Effects
Ocular: increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis and synechiae have been reported. Cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children and especially with 2%, including ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Other anticholinergic effects are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe toxicity includes coma, medullary paralysis and death.
Pregnancy: No animal reproduction studies have been conducted; whether fetal harm or an effect on reproductive capacity can occur is unknown, so administer only if clearly needed.
Lactation: Excretion in human milk is unknown; exercise caution in a nursing woman.
Psychotic reactions and behavioral disturbances reported in pediatric patients; increased susceptibility reported in infants, young children, and children with spastic paralysis or brain damage. Feeding intolerance and necrotizing enterocolitis may follow use in preterm infants; withhold feeding for 4 hours after examination and observe infants closely for at least 30 minutes.